{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:20:08Z","timestamp":1783635608777,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01726-w","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T13:17:56Z","timestamp":1774703876000},"page":"2499-2512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"1726_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405:583\u201396.","journal-title":"Lancet"},{"issue":"9","key":"1726_CR2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, et\u00a0al. European guideline (EuroGuiDerm) on atopic eczema: living update. Acad Dermatol Venereol. 2025;39(9):1537\u201366. https:\/\/doi.org\/10.1111\/jdv.20639.","journal-title":"Acad Dermatol Venereol"},{"key":"1726_CR3","unstructured":"European Medicines Agency Ebglyss (Lebrikizumab): summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ebglyss. Accessed 6 Dec 2025."},{"key":"1726_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et\u00a0al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188:740\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1726_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/bjd\/ljaf285","volume":"193","author":"RB Warren","year":"2025","unstructured":"Warren RB, de Bruin-Weller M, Tsianakas A, et\u00a0al. Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (Advantage). Br J Dermatol. 2025;193(5):876\u201388. https:\/\/doi.org\/10.1093\/bjd\/ljaf285.","journal-title":"Br J Dermatol"},{"key":"1726_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/17103568251361920","author":"T Hagino","year":"2025","unstructured":"Hagino T, Uchiyama A, Kosaka K, et\u00a0al. Thirty-six-week real-world effectiveness of lebrikizumab for different anatomical sites and clinical signs in atopic dermatitis: results from a prospective Japanese study. Dermatitis. 2025. https:\/\/doi.org\/10.1177\/17103568251361920.","journal-title":"Dermatitis"},{"key":"1726_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70089","author":"L Gargiulo","year":"2025","unstructured":"Gargiulo L, Bianco M, Ibba L, et\u00a0al. Reply to Hagino et\u00a0al.: \u201cImportance of Upadacitinib dose escalation prior to switch to lebrikizumab.\u201d J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70089.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1726_CR8","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s13555-025-01550-8","volume":"15","author":"G Avallone","year":"2025","unstructured":"Avallone G, Bombelli A, Gargiulo L, et\u00a0al. Effectiveness, safety, and health-related quality of life in moderate-to-severe atopic dermatitis treated with lebrikizumab: a 16-week nationwide retrospective cohort study. Dermatol Ther. 2025;15(12):3671\u201388. https:\/\/doi.org\/10.1007\/s13555-025-01550-8.","journal-title":"Dermatol Ther"},{"key":"1726_CR9","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2025.0045","author":"T Hagino","year":"2025","unstructured":"Hagino T, Uchiyama A, Onda M, et\u00a0al. 24-week real-world effectiveness and safety of lebrikizumab for atopic dermatitis in Japan: an analysis stratified by prior systemic therapy. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2025.0045.","journal-title":"Dermatitis"},{"key":"1726_CR10","first-page":"223","volume":"159","author":"G Argenziano","year":"2024","unstructured":"Argenziano G, Cusano F, Corazza M, et\u00a0al. Italian S3-Guideline on the treatment of atopic eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Ital J Dermatol Venereol. 2024;159:223\u201350.","journal-title":"Ital J Dermatol Venereol"},{"issue":"2","key":"1726_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.18176\/jiaci.0138","volume":"27","author":"JF Silvestre Salvador","year":"2017","unstructured":"Silvestre Salvador JF, Romero-P\u00e9rez D, Encabo-Dur\u00e1n B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78\u201388. https:\/\/doi.org\/10.18176\/jiaci.0138.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"11","key":"1726_CR12","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et\u00a0al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1726_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70180","author":"F Rob","year":"2025","unstructured":"Rob F, Kojanov\u00e1 M, Hercogov\u00e1 JT, et\u00a0al. Efficacy and safety evaluation of different lebrikizumab dosages in atopic dermatitis patients over 16 to 24 weeks: a BIOREP registry analysis. Int J Dermatol. 2025. https:\/\/doi.org\/10.1111\/ijd.70180.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1726_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et\u00a0al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024;192(1):36\u201345. https:\/\/doi.org\/10.1093\/bjd\/ljae404.","journal-title":"Br J Dermatol"},{"key":"1726_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CCID.S329442","volume":"17","author":"L Ibba","year":"2024","unstructured":"Ibba L, Gargiulo L, Vignoli CA, et\u00a0al. Practical use of upadacitinib in patients with severe atopic dermatitis in a real-world setting: a systematic review. Clin Cosmet Investig Dermatol. 2024;17:593\u2013604. https:\/\/doi.org\/10.2147\/CCID.S329442. (Published 2024 Mar 12).","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"16","key":"1726_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165727","volume":"14","author":"RM Izu Belloso","year":"2025","unstructured":"Izu Belloso RM, Juli\u00e1 Manresa M, Mart\u00ednez Pe\u00f1a N, et\u00a0al. Real-world clinical practice evaluation of tralokinumab in atopic dermatitis: a 52-week multi-center retrospective study in the Basque Country. J Clin Med. 2025;14(16):5727. https:\/\/doi.org\/10.3390\/jcm14165727. (Published 2025 Aug 13).","journal-title":"J Clin Med"},{"issue":"9","key":"1726_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094230","volume":"26","author":"K Walig\u00f3ra-Dziwak","year":"2025","unstructured":"Walig\u00f3ra-Dziwak K, Da\u0144czak-Pazdrowska A, Jenerowicz D. Long-term real-world effectiveness of dupilumab vs. upadacitinib in early treatment responders with atopic dermatitis: results from Central European health fund registry. Int J Mol Sci. 2025;26(9):4230. https:\/\/doi.org\/10.3390\/ijms26094230. (Published 2025 Apr 29).","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1726_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, et\u00a0al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943\u20138. https:\/\/doi.org\/10.36849\/JDD.2020.5422.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1726_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13555-024-01158-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, de Bruin-Weller M, Hong HC, et\u00a0al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(5):1145\u201360. https:\/\/doi.org\/10.1007\/s13555-024-01158-4.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01726-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01726-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:32Z","timestamp":1779949112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01726-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01726-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and design of the study. Material preparation and data analysis were conducted by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, and Sara Di Giulio. Data collection was performed by Mario Valenti, Gianluca Avallone, Martina Zussino, and Paolo Calzari. The first draft of the manuscript was written by Luigi Gargiulo and Luciano Ibba, and all authors commented on previous versions of the manuscript.\u00a0Alessandra Narcisi and Silvia M. Ferrucci performed the review and the editing of the final draft of the manuscript. Alessandra Narcisi, Silvia M. Ferrucci, Antonio Costanzo, and Angelo V. Marzano supervised the study. All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"No funding or sponsorship was received for this study or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Luigi Gargiulo has been a consultant and\/or speaker and has served as an advisory board member for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Galderma, Johnson and Johnson, Incyte, LEO Pharma, Novartis, Pierre Fabre, Pfizer,\u00a0Sanofi, and UCB Pharma. Luciano Ibba has been a consultant and\/or speaker and has served as an advisory board member for Almirall and LEO Pharma. Matteo Bianco has been a speaker for BMS. Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, and Boehringer Ingelheim. Mario Valenti is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Angelo V. Marzano has conflict of interest with AbbVie, Boehringer Ingelheim, Bristol Myers, Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi and UCB. Antonio Costanzo has served as an advisory board member and as consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Silvia M. Ferrucci has been principal investigator in clinical trials for AbbVie, Almirall, Galderma, Leo Pharma, Sanofi, Amgen, and Novartis, Bayer, and received honoraria for lectures for Novartis and Menarini. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Sara Di Giulio, Gianluca Avallone, Martina Zussino, and Paolo Calzari have nothing to declare. Luigi Gargiulo and Mario Valenti are Editorial Board members of\n                      Dermatology and Therapy\n                      . Luigi Gargiulo and Mario Valenti were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was granted by an institutional review board (Ethics Approval Committee Lombardia 3, protocol number Lebri-AD-2024). All patients received lebrikizumab, as per standard clinical practice, in accordance with European and Italian guidelines for the management of atopic eczema. For some of the included patients, Almirall provided the drug lebrikizumab through a Compassionate Use Program activated according to the DM 7\/9\/2017. The study was conducted following the principles of the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy. All patients provided written informed consent to participate in the study and for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}